Boston Scientific (BSX)
62.59
-3.10 (-4.72%)
NYSE · Last Trade: Apr 24th, 12:18 PM EDT
Detailed Quote
| Previous Close | 65.69 |
|---|---|
| Open | 65.80 |
| Bid | 62.59 |
| Ask | 62.61 |
| Day's Range | 62.51 - 65.97 |
| 52 Week Range | 59.38 - 109.50 |
| Volume | 5,937,863 |
| Market Cap | 89.12B |
| PE Ratio (TTM) | 32.26 |
| EPS (TTM) | 1.9 |
| Dividend & Yield | N/A (N/A) |
| 1 Month Average Volume | 18,364,526 |
Chart
About Boston Scientific (BSX)
Boston Scientific is a global medical technology company that specializes in the development, manufacturing, and marketing of a wide range of medical devices and solutions. The company focuses on providing innovative therapies for various medical conditions, including those affecting the cardiovascular, urology, and gastrointestinal systems, among others. Boston Scientific is committed to advancing patient care through its pioneering technologies, which are designed to improve outcomes and enhance the quality of life for patients around the world. Their product offerings include devices for minimally invasive procedures, enabling healthcare professionals to deliver high-quality care efficiently and effectively. Read More
News & Press Releases
These S&P500 stocks are gapping in today's sessionchartmill.com
Via Chartmill · April 24, 2026
Bragar Eagel & Squire, P.C. Litigation Partner Brandon Walker Encourages Investors Who Suffered Losses In Boston Scientific (BSX) To Contact Him Directly To Discuss Their Options
By Bragar Eagel & Squire · Via GlobeNewswire · April 23, 2026
NEW YORK, April 23, 2026 (GLOBE NEWSWIRE) -- Bernstein Liebhard LLP announces that a shareholder has filed a securities class action lawsuit on behalf of investors (the “Class”) who purchased or acquired the common stock of Boston Scientific Corporation (“Boston Scientific” or the “Company”) (NYSE: BSX) between July 23, 2025 and February 3, 2026, inclusive.
By Bernstein Liebhard LLP · Via GlobeNewswire · April 23, 2026
Medical device company Boston Scientific (NYSE:BSX) announced better-than-expected revenue in Q1 CY2026, with sales up 11.6% year on year to $5.20 billion. O...
Via StockStory · April 23, 2026
In today's session, there are S&P500 stocks with remarkable trading volume.chartmill.com
Via Chartmill · April 22, 2026
Boston Scientific Corp (NYSE:BSX) Reports Mixed Q1 2026 Results, Slight Revenue Miss Amid Profit Beatchartmill.com
Via Chartmill · April 22, 2026
Boston Scientific Corp (NYSE:BSX) Presents a Compelling Growth and Technical Setup Casechartmill.com
Via Chartmill · April 18, 2026
Rock-bottom prices don't always mean rock-bottom businesses. The stocks we're examining today have all touched their 52-week lows, creating a classic investo...
Via StockStory · April 23, 2026
On April 22, 2026, investors weigh a rare combo of earnings strength and softer long-term targets reshaping this medtech leader’s outlook.
Via The Motley Fool · April 22, 2026
Discover which S&P500 stocks are making waves on Wednesday.chartmill.com
Via Chartmill · April 22, 2026
Stay informed about the most active stocks in the S&P500 index on Wednesday's session.chartmill.com
Via Chartmill · April 22, 2026
Uncover the latest developments among S&P500 stocks in today's session.chartmill.com
Via Chartmill · April 22, 2026
BSX Q2 2025 Earnings Transcript
Via The Motley Fool · April 22, 2026
BSX Q3 2025 Earnings Transcript
Via The Motley Fool · April 22, 2026
BSX Q1 2026 Earnings Transcript
Via The Motley Fool · April 22, 2026
Medical device company Boston Scientific (NYSE:BSX) reported Q1 CY2026 results topping the market’s revenue expectations, with sales up 11.6% year on year to...
Via StockStory · April 22, 2026
NEW YORK, April 21, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against Boston Scientific Corporation (“Boston Scientific” or the “Company”) (NYSE: BSX). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext. 7980. Those who inquire by e-mail are encouraged to include their mailing address, telephone number, and the number of shares purchased.
By Pomerantz LLP · Via GlobeNewswire · April 21, 2026
Boston Scientific Corp. (NYSE:BSX) shares are in the spotlight on Tuesday after Stifel maintained a Buy rating and lowered its price target on the stock.
Via Benzinga · April 21, 2026
NEW YORK, April 21, 2026 (GLOBE NEWSWIRE) -- Bernstein Liebhard LLP announces that a shareholder has filed a securities class action lawsuit on behalf of investors (the “Class”) who purchased or acquired the common stock of Boston Scientific Corporation (“Boston Scientific” or the “Company”) (NYSE: BSX) between July 23, 2025 and February 3, 2026, inclusive.
By Bernstein Liebhard LLP · Via GlobeNewswire · April 21, 2026
Medical device company Boston Scientific (NYSE:BSX) will be reporting earnings this Wednesday before market hours. Here’s what you need to know. Boston Scien...
Via StockStory · April 20, 2026
Robbins LLP reminds stockholders that a class action was filed on behalf of all investors who purchased or otherwise acquired Boston Scientific Corporation (NYSE: BSX) common stock between July 23, 2025 and February 3, 2026. Boston Scientific is a global company that develops, manufactures, and markets medical devices used across various specialties.
By Robbins LLP · Via Business Wire · April 20, 2026
Top S&P500 movers in Monday's sessionchartmill.com
Via Chartmill · April 20, 2026
What's going on in today's session: S&P500 moverschartmill.com
Via Chartmill · April 20, 2026
NEW YORK, April 18, 2026 (GLOBE NEWSWIRE) --
By The Rosen Law Firm PA · Via GlobeNewswire · April 18, 2026
Generating cash is essential for any business, but not all cash-rich companies are great investments. Some produce plenty of cash but fail to allocate it eff...
Via StockStory · April 17, 2026
